Updates on 503A Compounding: The Impact of Drug Shortages
The FDA’s temporary Guidance for 503A compounding of shortage drugs was meant to be temporary and withdrawn once COVID-19 ended.
Frier Levitt Martham Rumore Drug Evaluation Research National Association Of Boards Pharmacy Biologics Price Competition Innovation Act
Source: pharmacytimes.com